Abstract
Background: The aim of this project was to investigate the sensitivity of CA 15-3, CEA and HER2 in the early diagnosis of metastatic breast cancer.
Methods: Serial serum values of CA 15-3, CEA and HER2 were determined in 107 patients with recurrence after breast cancer. Fifteen of the patients had primary disseminated disease, nine patients only developed local recurrence during the follow-up period and the remaining 83 developed distant metastases.
Results: In the group of patients with distant metastatic disease (n=83), elevated serum levels of CA 15-3 (>32.4 U/mL), CEA (>2.5 µg/L for non-smokers and >10 µg/L for smokers) and HER2 (>15 µg/L) were found in 49.4%, 38.6% and 32.5%, respectively, at the time of diagnosis of recurrence. CA 15-3 was significantly better than HER2 (p=0.027). The most sensitive combination was obtained using CA 15-3/CEA (60.2%) or CA 15-3/HER2 (57.8%). Combining all three tumour markers raised the sensitivity to 63.9%. In the subgroup of patients with tissue HER2+ tumours, the sensitivity of HER2 increased to 55.6%. The best combination in this group was CEA/HER2 (66.7%). In the subgroup of patients with tissue HER2− tumours, CA 15-3 was significantly better. The best combination was CA 15-3/HER2 or CA 15-3/CEA with a sensitivity of 55.8% and 59.6%, respectively.
Conclusions: The combination of several tumour markers enhances the sensitivity for detection of metastatic breast cancer. We recommend HER2 or the combination of CEA and HER2 in tissue HER2+ and CA 15-3 or the combination of CA 15-3 and CEA in tissue HER2−.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Research funding: Siemens supported the study by offering reagents at a discount, but did not influence the protocol or the writing of the manuscript.
Employment or leadership: None declared.
Honorarium: Ivan Brandslund has received a fee for lectures from Siemens.
References
1. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Teat Rev 2000;26:91–102.10.1053/ctrv.1999.0151Search in Google Scholar
2. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345–51.10.1373/clinchem.2005.059832Search in Google Scholar
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287–312.10.1200/JCO.2007.14.2364Search in Google Scholar
4. European group on tumour marker. EGTM guideline for breast cancer. Available from: http://www.egtm.eu/recommendations.html. Accessed 22 May, 2012.Search in Google Scholar
5. Molina R, Escudero JM, Munoz M, Auge JM, Filella X. Circulating levels of HER-2/neu oncoprotein in breast cancer. Clin Chem Lab Med 2012;50:2–21.10.1515/cclm.2011.822Search in Google Scholar
6. Sørensen PD, Jacobsen EH, Langkjer ST, Bokmand S, Østergaard B, Olsen DA, et al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 2009;47:1117–23.10.1515/CCLM.2009.241Search in Google Scholar
7. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010;201:102–10.10.1016/j.cancergencyto.2010.05.015Search in Google Scholar
8. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1995;1241:407–23.10.1016/0304-4157(95)00014-3Search in Google Scholar
9. Hilkens J, Vos HL, Wesseling J, Peterse J, Storm J, Boer M, et al. The expression levels of episialin in human carcinomas are sufficiently high to potentially interfere with adhesion and protome metastasis. In: Calvo F, Crepin M, Magdelenat H, editors. Breast cancer advances in biology and therapeutics. Rontrouge, France: John Libbey Eurotext, 1996:281–8.Search in Google Scholar
10. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57:327–34.10.1016/0092-8674(89)90970-7Search in Google Scholar
11. Hammerström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67–81.10.1006/scbi.1998.0119Search in Google Scholar
12. Clarke C, Hine KR, Dykes PW, Whitehead TP, Whitfield AG. Carcinoembryonic antigen and smoking. J R Coll Physicians Lond 1980;14:227–8.Search in Google Scholar
13. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112:53–67.Search in Google Scholar
14. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266: 1716–20.10.1016/S0021-9258(18)52354-1Search in Google Scholar
15. Molina R, Jo J, Filella X, Bruix J, Castells A, Hauge M, et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997;18:188–96.10.1159/000218029Search in Google Scholar
16. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumour Biol 1998;19:1–20.10.1159/000056500Search in Google Scholar
17. Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers 2009;14:130–6.10.1080/13547500902770090Search in Google Scholar
18. Valenzuela P, Mateos S, Tello E, López-Bueno MJ, Garrido N, Gaspar MJ. The contribution of the CEA marker to CA 15-3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 2003;24: 60–2.Search in Google Scholar
19. Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D’Amico DF. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 1999;19:4485–9.Search in Google Scholar
20. Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995;36:41–8.10.1007/BF00690183Search in Google Scholar
21. Coveney EC, Geraghty JG, Sherry F, McDermott EW, Fennelly JJ, O’Higgins NJ, et al. The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers 1995;10:35–41.10.1177/172460089501000107Search in Google Scholar
22. Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res 2000;20:4751–5.Search in Google Scholar
23. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by ‘early’ salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997;76:1106–11.10.1038/bjc.1997.515Search in Google Scholar
24. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, et al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 2007;27:1963–8.Search in Google Scholar
25. Kokko R, Holli K, Hakama M. CA 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002; 38:1189–93.10.1016/S0959-8049(01)00429-4Search in Google Scholar
26. Safi F, Kohler I, Röttinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207–14.10.1177/172460088900400405Search in Google Scholar
27. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001;7:2357–62.Search in Google Scholar
28. Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, et al. Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumour Biol 2001;22:367–73.10.1159/000050639Search in Google Scholar
29. Jezersek B, Cervek J, Rudolf Z, Novaković S. Clinical evaluation of potential usefulness of CEA, CA 15-3 and MCA in follow-up of breast cancer patients. Cancer Lett 1996;110:137–44.10.1016/S0304-3835(96)04473-4Search in Google Scholar
30. Iwase H, Kobayashi S, Itoh Y, Fukuoka H, Kuzushima T, Iwata H, et al. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Treat 1995;33:83–8.10.1007/BF00666074Search in Google Scholar
31. Al-Jarallah MA, Behbehani AE, el-Nass SA, Temim L, Ebraheem AK, Ali MA, et al. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 1993;19:74–9.Search in Google Scholar
32. Barros AC, Fry W Jr., Nazario AC, Santos MO, Sato MK. Experience with CA 15.3 as a tumor marker in breast cancer. Eur J Surg Oncol 1994;20:130–3.Search in Google Scholar
33. Sölétormos G, Nielsen D, Schiøler V, Skovsgaard T, Winkel P, Mouridsen HT, et al. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol 1993;4:861–9.Search in Google Scholar
34. Safi F, Kohler I, Röttinger E, Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991;68:574–82.10.1002/1097-0142(19910801)68:3<574::AID-CNCR2820680322>3.0.CO;2-BSearch in Google Scholar
35. Colomer R, Ruibal A, Genollá J, Rubio D, Del Campo JM, Bodi R, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989;13:123–33.10.1007/BF01806524Search in Google Scholar
36. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 1991;200:81–93.10.1016/0009-8981(91)90080-VSearch in Google Scholar
37. Sütterlin M, Bussen S, Trott S, Caffier H. Predictive value of CEA and CA 15-3 in the follow-up of invasive breast cancer. Anticancer Res 1999;19:2567–70.Search in Google Scholar
38. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrai P, Anselmi L, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs. MCA and MCA-CA15.3 vs. CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006;6:269–77.10.1186/1471-2407-6-269Search in Google Scholar
39. D’Alessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, et al. Serum tissue polypeptide specific antigen (TPS): a complementary tumor maker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat 2001;68:9–19.10.1023/A:1017903724176Search in Google Scholar
40. Baskić D, Ristić P, Pavlović S, Arsenijević N. Serum HER2 and CA 15-3 in breast cancer patients. J BUON 2004;9:289–94.Search in Google Scholar
41. Baskić D, Ristić P, Matić S, Bancović D, Popović S, Arsenijević N. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. Biomarkers 2007;12:657–67.10.1080/13547500701520563Search in Google Scholar
42. Fehm T, Jäger W, Krämer S, Sohn C, Solomayer E, Wallwiener D, et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 2004;24:1987–92.Search in Google Scholar
43. Pichon MF, Hacene K, Guepratte S, Neumann R. Serum HER-2 extracellular domain (ECD) before the first metastatis in 128 breast cancer patients. Clin Lab 2004;50;163–70.Search in Google Scholar
44. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the c-erb-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000;89:329–36.10.1002/1097-0215(20000720)89:4<329::AID-IJC3>3.0.CO;2-PSearch in Google Scholar
45. Molina R, Jo J, Zanón G, Filella X, Farrus B, Muñoz M, et al. Utility of C-erB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer 1996;74:1126–31.10.1038/bjc.1996.501Search in Google Scholar
46. Molina R, Jo J, Filella X, Zanón G, Farrus B, Muñoz M, et al. C-erB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 1999;19:2551–5.Search in Google Scholar
47. Tafe LJ, Tsongalis GJ. The human epidermal growth factor receptor 2 (HER2). Clin Chem Lab Med 2012;50:23–30.Search in Google Scholar
48. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429–34.10.1158/1078-0432.CCR-06-3045Search in Google Scholar
©2013 by Walter de Gruyter Berlin Boston
